Ipamorelin

Ipamorelin is a peptide-selective agonist of growth hormone releasing peptides/growth hormone secretagogue receptors (GHS) and a growth hormone secretagogue.

Ipamorelin is a pentapeptide (AIb-his-D-2-NAL-D-Phit-Lys-NH2) that has shown high GH-releasing potency and efficacy in vitro and in vivo. As a result of a major chemical program, ipamorelin was found in a range of compounds lacking Ala-Trp, the central dipeptide of growth hormone releasing peptide (GHRP) -1.

Ipamorelin, also known as NNC-26-0161, is a a ghrelin mimetic. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Ipamorelin may ameliorate the symptoms in patients with POI. Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Tha mòran fhactaraidhean àrd-inbhe againn le co-obrachadh domhainn, a bheir dhut toraidhean àrd-inbhe agus prìsean farpaiseach. Agus is urrainn dhuinn cuideachd lasachaidhean a thoirt seachad airson mòr-cheannach. Tha an ùine lìbhrigidh timcheall air 3-20 latha às deidh dearbhadh pàighidh.

In vitro experiments, ipamorelin released GH from primary rat pituitary cells with similar efficacy to GHRP-6. Pharmacological analyses using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly show that, like GHRP-6, Ipamorelin /Ipamorelin stimulates GH release through GHRP-like receptors.